Agenda

Format
The meeting will be chaired and moderated by Professor Philip Scheltens chair of World Dementia Council, Professor Emeritus at Amsterdam University Medical Centers and head of the EQT Life Sciences Dementia Fund. It will be a series of sessions beginning with diagnosis through treatments to our ultimate goal of prevention. Each session will have short introductions from panelists and will be followed up by a open mic discussion moderated by Professor Scheltens.

0830 Registration | coffee will be served

0900 Welcome
Welcome to the day and scene setting

Speakers
Lenny Shallcross  
Executive Director  
World Dementia Council

Philip Scheltens  
Chair World Dementia Council  
and summit host

0915 Morning sessions | 30 minute coffee break mid morning

Session one | Clinical meaningfulness
There is no single interpretation of clinical meaningfulness from the clinician’s standpoint, from the scale standpoint and also from the patient and carer’s standpoint. There is no resolute answer and no one single measure of clinical meaningfulness that will encompass this diversity. This session will explore the different perspectives and the implications this has on treatment approval.

Speakers
Professor John Harrison  
Chief Scientific Officer  
Scottish Brain Sciences

Professor Gillian Leng  
The Dean for the Royal Society of Medicine former CEO of NICE

Professor Mark McClellan  
Dukes University,  
Former Director of FDA

Dr William Reichman  
President & CEO  
of Baycrest Health

Session two | Equity
This session will address the impact of developments in biomarkers, technology and treatments, pharmacological and non-pharmacological will have on dementia research, diagnosis, health and social care. We know from disease areas that treatments and innovation more broadly can increase inequity. Dementia diagnosis and care today is already very unequal between countries and within them. Is it inevitable over the decade ahead we will see greater inequity? Or is it possible, practical and desirable for policy makers, civil society, and the dementia community to both deliver new ways of diagnosing, treating and preventing disease and simultaneously reducing inequity?

Speakers
Howard Bergman  
MD, FCFP, FRCP, FCAHS Assistant Dean,  
International Affairs, Faculty of Medicine & Health Sciences; Professor of Family Medicine, Medicine & Oncology and the Institute for Health and Social Policy, McGill University

Dr Tarun Dua  
Lead for Brain Health  
World Health Organization

Professor Ricardo Allegri  
Director of the Ageing and Memory Centre  
Fleni Neurological Institute

Paola Barbarino  
CEO Alzheimer’s Disease International
### Session three | Biomarkers, where do we stand?

This session will focus on the development of biomarkers (there is a subsequent session on when to diagnose and the questions around that). Digital, plasma and blood in AD and other forms of dementia. Where we think we will be in five or ten years, and cover some of the problems the field needs to be addressed to get there.

**Speakers**

- **Professor Karen Duff**  
  Director UK Dementia Research Institute
- **Dr Ivonne Suridjan**  
  Director Global Clinical Development & & Neurology Indication Leader, Roche Diagnostics Ltd
- **Provost Professor Arthur Toga**  
  Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioural Sciences, University of Southern California
- **Brad O’Connor**  
  Chief Executive Cogstate
- **Professor Charlotte Teunissen**  
  Head of the Neurology Lab Amsterdam University Medical Center

| 1230 Lunch |

| 1330 Afternoon sessions | coffee break mid afternoon |

### Session four | A timely diagnosis

This session will follow on directly from a discussion on development of biomarkers and will focus on when and why we should diagnose someone, now and in the years ahead. From an individual and a public policy standpoint when in the development of the disease we want to diagnose someone. Practically and ethically, what is possible?

**Speakers**

- **Fiona Carragher**  
  Director of Research and Influencing Clinical Alzheimer’s Society
- **Phyllis Ferrell**  
  Head of Global Engagement for AD, Eli Lilly
- **Professor Giovanni Frisoni**  
  Clinical Neurologist, Full Professor of Neuroscience, Geneva University Hospitals
- **Jetske van der Schaar**  
  PhD Student Amsterdam University Medical Center
- **Professor Alistair Burns CBE**  
  Professor of Old Age Psychiatry NHS England NHS England Dementia Lead
- **Laurence Geller CBE**  
  Chancellor, University of West London
- **Ernst van Koesveld**  
  Director General Long-Term Care, Government of Netherlands
- **Professor Anja Leist**  
  Associate Professor in Public Health & Ageing; Vice-Head, Institute for Research on Socio-Economic Inequality, University of Luxembourg; Co-Chair of World Young Leaders in Dementia (WYLD)
- **Dr Andrew Trister**  
  Deputy Director, Health Artificial Intelligence, Bill & Melinda Gates Foundation
**Session six | The case for prevention interventions?**

We will conclude the conversation with session on preventing disease, beginning with non-pharmacological interventions. Across clinical medicine there is a recognition that to manage future health care demands we have to get much better at primary and secondary disease, alongside early diagnosis. Few countries have a structure to deliver prevention (or early diagnosis) and health systems are geared to incentivise activity not outcomes. To manage an ageing population people need to take greater responsibility for their health. To what extent can dementia incentivise people to do that? And to what extent can health systems deploy interventions, particularly in later life, that are backed by robust scientific validation?

*Speakers*

- **Matthew Baumgart**
  Senior Director of Public Policy for the Alzheimer’s Association

- **Professor Miia Kivipelto**
  Professor in Clinical Geriatrics, Karolinska Institutet

- **Professor Johannes Streffer**
  Chief Medical Officer AC Immune

- **George Vradenburg**
  Founding Chairman, Davos Alzheimer’s Collaborative (DAC); Convener, Global CEO Initiative in Alzheimer’s (CEOi); Chairman, Global Alzheimer’s Platform Foundation (GAP) Chairman and Co-Founder of UsAgainstAlzheimer’s (UsA2); Founding Member, World Dementia Council; Founding Member, US NAPA Advisory Council

---

**Session seven | The development of future treatments**

This session will consider what the landscape for future treatments looks like: new combination therapies, new targets and new methods of delivery. There remains a significant need to improve the understanding of basic science and to accelerate the development of trials and the speed of treatments coming to market. Data offers huge potential, but funding is also important. This session will conclude the day and hopefully draw on all of the discussion that has taken place.

*Speakers*

- **Dr Heather Snyder**
  Vice President Medical & Scientific Relations Alzheimer’s Association

- **Dr Howard Fillit**
  Co-Founder & Chief Science Officer of the Alzheimer’s Drug Discovery Foundation

- **Dr Stacie Weninger**
  President, FBRI

- **Professor Caleb Webber**
  Director of Informatics, UK Dementia Research Institute

- **Dr Laurence Barker**
  Partner Dementia Discovery Fund

---

**1700 Closing session**

*Speakers*

- **George Freeman**
  Minister for Science, Research and Innovation, UK Government

- **Professor Philip Scheltens**
  Chair World Dementia Council and summit host

- **Lenny Shallcross**
  Executive Director World Dementia Council

---

**1730 Drinks reception**